Tebra vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Practice management platform for 130K independent physicians from Kareo+PatientPop merger; EHR, billing, and patient acquisition marketing for small practices competing with athenahealth.
About
Tebra (formerly Kareo + PatientPop) is a cloud-based practice management and digital health platform for independent healthcare practices — providing practice management software, electronic health records (EHR), billing and revenue cycle management, patient engagement, and healthcare marketing tools specifically designed for small independent physician practices. Formed through the merger of Kareo (practice management/billing) and PatientPop (healthcare marketing/patient acquisition) in 2022, Tebra serves approximately 130,000 healthcare providers at independent practices across primary care, mental health, dermatology, and specialty care.\n\nTebra's platform addresses the full operational needs of a small medical practice: EHR documentation with templates for common visit types, automated patient appointment reminders and forms, insurance eligibility verification and claims submission, payment collection from patients, and online reputation management (Google reviews, healthcare directory listings). The combined Kareo+PatientPop heritage means Tebra uniquely covers both the clinical and administrative workflow alongside the digital marketing capabilities independent practices need to attract new patients.\n\nIn 2025, Tebra competes in the small practice EHR and practice management market against athenahealth, drchrono, Jane App, and Practice Fusion for independent physician practice software. The independent practice market faces significant headwinds from hospital consolidation — independent physician practices have steadily been acquired into health system employment or affiliated networks, shrinking the addressable market. Tebra's 2025 strategy focuses on the growing behavioral health segment (mental health practices are growing and need modern practice management tools), telehealth integration (virtual visit capability within the EHR workflow), and improving revenue cycle management automation to help practices collect more of what they bill.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.